Dr. Jonathan C. Trent, a medical oncologist specializing in Sarcoma and Connective Tissue Medical Oncology at Sylvester, is available to discuss a wide range of issues related to Sarcoma research and experimental therapeutics. He and collaborators are involved in multiple ASCO23 presentations, including:
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.
Racial and ethnic disparities in presentation and outcomes of patients with gastrointestinal stromal tumors (GIST) in the era of targeted therapy.
The impact of hispanic ethnicity in presentation and outcomes of patients with synovial sarcoma.
While in Chicago, but not as part of ASCO, he will also present a CME for tumor agnostic precision oncology.
Mesothelioma, Lung Cancer and Global Oncology (B-Roll/Video Available)
Dr. Gilberto Lopes, a thoracic medical oncologist, is chief of medical oncology, medical director for international programs and associate director for global oncology at Sylvester. He is the Editor-in-Chief for the specialized Journal of Global Oncology, which is the primary source for global oncology studies. Dr. Lopes is available to discuss a wide range of issues related to mesothelioma and lung cancer research, as well as global health and the ATOM Coalition. He and collaborators are involved in several ASCO23 abstract presentations, posters and publications. Downloadable B-roll/Video is available here.
Examining molecular testing practices and targeted therapy use in advanced/metastatic non-small cell lung cancer (mNSCLC): A quality improvement initiative across ten community cancer centers.
The association of race and curative-intent treatment with mortality outcomes among early-stage NSCLC.
Cancer deaths in the state of Sao Paulo, Brazil: Is there a solution for disparities among private and public services?
Assessing gender disparities in young patients with lung cancer among a diverse urban population.
The Potential for Using the ATOM Model to Impact Cancer Mortality in LMICs
Dr. Marijo Bilusic, leads Sylvester’s Genitourinary Cancers Site Disease Group where he treats genitourinary tumors (adrenal, kidney, prostate, bladder, and testis). His current research interests focus on tumor immunology and the development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, immune modulators or immune checkpoint inhibitors, not only as monotherapies but in combination with other therapies as part of an immuno-oncology programmatic effort. He is board-certified in medical oncology, hematology, and internal medicine, and is available to discuss abstracts, presentations and research findings related to genitourinary cancers.
Breast Cancer and Breast Cancer Surgery (B-Roll/Video Available)
Dr. Kristin E. Rojas is a Sylvester breast cancer surgeon and a board-certified gynecologic surgeon. She is one of the few dual-trained physicians with expertise in both breast cancer surgery and women’s sexual health. Her research interests include the impact of perioperative opioids on the gut microbiome, breast cancer surgical decision making, and women’s sexual health after cancer. She is a national leader in treating sexual dysfunction in female patients undergoing cancer treatment and an expert on the topics of menopause symptom management in female cancer patients, optimizing women’s sexual health in cancer survivorship, and minimizing the need for superfluous opioid prescribing in cancer surgery. At ASCO23, she will chair “A Juggling Act: Managing the Toxicity of Estrogen Deprivation for Patients With Breast Cancer,” a special educational session addressing quality of life for patients receiving endocrine therapy for breast cancer, advances in improving sexual health, fertility preservation, and bone health. Downloadable B-roll/Video is available here.
Florida has the second-highest incidence of melanoma in the United States. Located in Miami, Dr. Jose Lutzky leads Cutaneous Oncology Services at Sylvester and is director of the Clinical Trials Coordinating Unit. Triple board-certified in hematology, oncology and internal medicine, he is part of a multidisciplinary team of cancer experts and researchers focusing on new and better treatment options.
Gastrointestinal (G.I.) Cancers (B-Roll/Video Available)
Dr. Shria Kumar is a clinical epidemiologist and gastroenterologist. A member of Sylvester’s Cancer Control Program, her research focuses on screening, early detection and early management of GI cancers, along with identifying and improving cancer disparities. Dr. Kumar is the recipient of a 2023 Conquer Cancer Career Development Award from ASCO. With this funding, she plans to research the impact of weight trajectory on colorectal cancer risk and mortality in a diverse patient population. Kumar also plans to develop a comparative analysis of body-mass index and body composition measurements to better guide clinicians who use weight-loss interventions with their patients. Downloadable B-roll/Video is available here.
Thyroid Cancer (B-Roll/Video Available)
Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as targeted therapies and other new medications emerge, surgery for certain patients may become more of a secondary option if those treatments fail. This new context could potentially change how some procedures are conducted. Sylvester otolaryngologist and head and neck surgeon Dr. Zoukaa Sargi, will join a June 2 ASCO panel discussion on thyroid cancer care. Sargi specializes in head and neck cancers and will provide a surgeon’s perspective on how thyroid cancer treatment is evolving. Downloadable B-roll/Video is available here.
Solid and CNS Tumors
Dr. Macarena de la Fuente, chief of Neuro-Oncology at Sylvester, whose research focuses on developing treatments for primary brain tumors, will present results from a Phase 1/2a study on the safety and efficacy of the Novel BRAF Inhibitor FORE8394 in patients with advanced solid and central nervous system tumors. The study showed the experimental, targeted therapy may be effective in treating BRAF-altered solid tumors, including mutations not previously targeted with a benign safety profile. The study targeted a wide range of cancers, including high-grade glioma, low-grade glioma, colorectal cancer, papillary thyroid cancer, melanoma, pancreatic cancer, ovarian cancer, non-small cell lung cancer, anaplastic thyroid cancer, and others.
# # #
Adolescents who show signs of alcohol dependence are more likely to develop depression by their mid-20s, according to a new study led by UCL (University College London) and University of Bristol researchers.
Drinking large amounts of alcohol regularly, but with no signs of dependency, did not predict depression risk, according to the findings published in The Lancet Psychiatry.
Co-lead author Dr Gemma Lewis (UCL Psychiatry) said: “By using a large, longitudinal dataset, we have found evidence that problematic drinking patterns in late adolescence may increase the risk of developing ...
The UK’s growing mismatch between the fish we catch and the fish we want to eat has clear implications for our future food security, according to new research.
Led by the University of Essex and the Centre for Environment Fisheries and Aquaculture Science (Cefas), the study, published in the international peer-reviewed journal Reviews in Fish Biology and Fisheries, for the first time offers a comprehensive, long-term analysis of how major policy changes in the past 120 years have influenced patterns in UK seafood production, trade and consumption.
It shows that even if we changed our fish-eating habits away from choosing flaky white fish such as cod ...
A new study of 3,745 families from across the UK demonstrates a “sizeable” gap in the financial knowledge of children depending on which socio-economic group they come from.
The research highlights significant inequalities in young people’s financial capabilities, with the results pointing toward disadvantaged children not developing key financial skills.
In findings published in the peer-reviewed British Journal of Educational Studies, an expert team from UCL are calling for a greater emphasis on developing financial skills amongst children starting at primary school, particularly aimed towards those from disadvantaged social backgrounds, with “a particular need ...
MIAMI, FLORIDA (June 1, 2023) – Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as targeted therapies and other new medications emerge, surgery for certain patients may become more of a secondary option if those treatments fail. This new context could potentially change how some procedures are conducted.
Otolaryngologist and head and neck surgeon Dr. Zoukaa Sargi, will join a June 2 panel discussion on thyroid cancer care ...
In a multicenter phase 1 and 2 trial (BRUIN, NCT03740529), researchers from leading cancer centers across the globe, including the Medical College of Wisconsin (MCW) in Milwaukee, tested Bruton tyrosine kinase inhibitor (BTKi), pirtobrutinib, in patients with pre-treated mantle cell lymphoma (MCL). Results of the study, which assessed the efficacy of the drug in a cohort of 90 patients with poor survival prognosis, demonstrated the reversible BTKi drug to be both safe and effective in achieving inhibition of defective B-cells. The results were published by the Journal of Clinical Oncology on May 16.
MCL is an aggressive, rare subtype of ...
Beech leaf disease is an emerging threat to North American forest ecosystems. It was first discovered in northeastern Ohio in 2012, and has already spread to 12 additional U.S. states and Canadian provinces. At first the cause of the disease was unknown, and the sick and dying trees were diagnosed on symptoms alone: Dark banding along the leaf veins and shriveled, leathery leaves. But in 2017, nematodes were found in diseased leaves, and by 2020 we had the answer: A newly recognized subspecies of the wormlike creature, Litylenchus crenatae mccannii, was definitely associated with the symptoms.
In order to monitor the spread of the disease, to understand the nemotode’s ...
(MEMPHIS, Tenn. – June 01, 2023) Infections and other diseases can cause red blood cells to rupture, releasing the oxygen-binding molecule hemoglobin, which breaks down into heme. Free heme can cause significant inflammation and organ damage, leading to morbidity and mortality. Researchers from St. Jude Children’s Research Hospital discovered NLRP12, an innate immune pattern recognition receptor, to be the key molecule responsible for inducing inflammatory cell death and pathology in response to heme combined with other cellular damage or infection. The finding provides a new potential drug target to prevent morbidity in certain illnesses. ...
HOUSTON – (June 1, 2023) – An international team of marine biologists has discovered the remnants of ancient RNA viruses embedded in the DNA of symbiotic organisms living inside reef-building corals.
The RNA fragments are from viruses that infected the symbionts as long ago as 160 million years. The discovery is described in an open-access study published this week in the Nature journal Communications Biology, and it could help scientists understand how corals and their partners fight off viral infections today. But it was a surprising find because most RNA viruses are not known ...
Davis, CA - The Necrotizing Enterocolitis (NEC) Society is thrilled to release the Neonatal Probiotics Toolkit. The Toolkit provides structure to clinicians in neonatal intensive care units (NICUs) as they consider the complex process and decision of whether to implement probiotics to help prevent NEC. The Toolkit is not a recommendation for or against the routine use of probiotics in the NICU, nor for or against the use of any product or preparation method.
NICUs and clinicians are encouraged to use the Toolkit to foster thoughtful, intentional dialogue and inclusive conversations amongst key stakeholders in the NICU, including the need for patient-families to understand ...
Tumors are composed of rapidly multiplying cancer cells. Understanding which biochemical processes fuel their relentless growth can provide hints at therapeutic targets.
Researchers from Washington University in St. Louis have developed a technology to study tumor growth in another dimension — literally. The scientists established a new method to watch what nutrients are used at which rates spatially throughout a tissue.
By using this multidimensional imaging approach, they identified pathways whose activities are uniquely elevated in brain cancer, offering clues for potential treatment strategies. The study was published May 19 in Nature Communications.